Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 7/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30219759 | 1.00 | ADRB2 (0.38) | ADRB2DAOHCRTR1HCRTR2KCNH2 | |
| SCHEMBL25695773 | 0.84 | CYP3A4 (0.39) | ADRB2KCNH2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL30219785 | 0.83 | AKR1C3 (0.40) | DAOCYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL30219781 | 0.83 | AKR1C3 (0.40) | DAOCYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL24046370 | 0.75 | CYP1A2 (0.46) | DAOCYP3A4CYP2D6 | |
| SCHEMBL30219766 | 0.75 | CYP1A2 (0.46) | DAOCYP3A4CYP2D6 | |
| SCHEMBL24046632 | 0.74 | TSHR (0.40) | ADRB2DAOKCNH2CYP3A4CYP2D6 | |
| SCHEMBL30219772 | 0.74 | TSHR (0.40) | ADRB2DAOKCNH2CYP3A4CYP2D6 | |
| SCHEMBL24046693 | 0.70 | SIGMAR1 (0.44) | DAOCYP3A4CYP2D6 | |
| SCHEMBL30219730 | 0.70 | SIGMAR1 (0.44) | DAOCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192644-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192644-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021236885-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192644-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | IKZF2, IKZF1, NUTF2 | ADRB2 1832/4885DAO 3563/4885HCRTR1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.